5-acetylpyrazinecarboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-acetylpyrazinecarboxamide
• 英文别名: 5-acetylpyrazine-2-carboxamide
• 化学式: C₇H₇N₃O₂
• mdl: MFCD11100140
• 分子量: 165.151
• InChiKey: ALPVAENMJMTCLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  85.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-acetylpyrazinecarboxamide 在 盐酸 、 甲醇 作用下， 生成 ethyl 5-ethoxypyrazine-2-carboxylate
  参考文献：
  名称：

  [EN] FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS
  [FR] DÉRIVÉS D'AMINODIHYDROTHIAZINE CONDENSÉS UTILES EN TANT QU'INHIBITEURS DE BACE

  摘要：

  本发明涉及一种公式(I)的融合氨基二氢噻嗪衍生物，其中X为氢或氟；A为CH或N；Y为甲基、乙基、单氟甲基、二氟甲基、三氟甲基、二氟乙基、甲氧基、乙氧基、甲氧甲基或-C≡N；以及其药学上可接受的盐；该化合物具有Αβ产生抑制作用或BACEl抑制作用，并且可用作由Αβ引起且以阿尔茨海默病型痴呆为特征的神经退行性疾病的预防或治疗剂。

  公开号：

  WO2012098213A1
• 作为产物：
  描述：

  吡嗪酰胺 、 丙酮酸 在 ammonium persulfate 、 硫酸 、 silver nitrate 作用下， 反应 2.0h， 以55%的产率得到5-acetylpyrazinecarboxamide
  参考文献：
  名称：

  Sato, Nobuhiro; Kadota, Hisashi, Journal of Heterocyclic Chemistry, 1992, vol. 29, p. 1685 - 1688

  摘要：

  DOI：

文献信息

• [EN] FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINODIHYDROTHIAZINE CONDENSÉS UTILES EN TANT QU'INHIBITEURS DE BACE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2012098213A1

  公开（公告）日：2012-07-26

  The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or -C≡N; and pharmaceutically acceptable salts thereof; which compound has an Αβ production inhibitory effect or a BACEl inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Αβ and typified by Alzheimer-type dementia.

  本发明涉及一种公式(I)的融合氨基二氢噻嗪衍生物，其中X为氢或氟；A为CH或N；Y为甲基、乙基、单氟甲基、二氟甲基、三氟甲基、二氟乙基、甲氧基、乙氧基、甲氧甲基或-C≡N；以及其药学上可接受的盐；该化合物具有Αβ产生抑制作用或BACEl抑制作用，并且可用作由Αβ引起且以阿尔茨海默病型痴呆为特征的神经退行性疾病的预防或治疗剂。
• [EN] FUSED AMINODIHYDRO-OXAZINE DERIVATIVES<br/>[FR] DÉRIVÉS CONDENSÉS D'AMINODIHYDRO-OXAZINE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2011009898A1

  公开（公告）日：2011-01-27

  A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  通用式（I）或其药用可接受盐或其溶剂的化合物，其中环A是C6-14芳基或类似物，L是-NReCO-或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基或类似物，Y是单键或类似物，Z是C1-3烷基或类似物，R1和R2各自独立地是氢原子或类似物，R3、R4、R5和R6各自独立地是氢原子、卤素原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。
• 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders
  申请人：Chen L. Yuhpyng

  公开号：US20050107381A1

  公开（公告）日：2005-05-19

  The present invention relates to compounds of the Formula wherein R 1 , R 1a , R 1b , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , X, Y, W, U, Z, m and n are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

  本发明涉及公式I的化合物，其中R1，R1a，R1b，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12，X，Y，W，U，Z，m和n如所定义。公式I的化合物具有抑制Aβ肽生成活性。本发明还涉及含有公式I化合物的制药组合物和治疗疾病的方法，例如神经退行性疾病，例如阿尔茨海默病，在哺乳动物中治疗。
• FUSED AMINODIHYDRO-OXAZINE DERIVATIVES
  申请人：Ellard John Mark

  公开号：US20120202804A1

  公开（公告）日：2012-08-09

  A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C 6-14 aryl group or the like, L is —NR e CO— or the like (wherein R e is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a single bond or the like, Z is a C 1-3 alkylene group or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  化合物由通式（I）或其药学上可接受的盐或溶剂化物表示，其中环A是C6-14芳基或类似物，L是-NReCO-或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基或类似物，Y是单键或类似物，Z是C1-3烷基或类似物，R1和R2各自独立地是氢原子或类似物，而R3、R4、R5和R6各自独立地是氢原子、卤原子或类似物。该化合物具有Aβ产生抑制作用或BACE1抑制作用，并且可用作预防或治疗由Aβ引起的、以阿尔茨海默型痴呆为代表的神经退行性疾病的药物。
• Fused Aminodihydro-Oxazine Derivatives
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2653473A1

  公开（公告）日：2013-10-23

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  由通式表示的化合物： 或其药学上可接受的盐或其溶液，其中环 A 是 C6-14 芳基或类似物，L 是 -NReCO- 或类似物（其中 Re 是氢原子或类似物），环 B 是 C6-14 芳基或类似物，X 是 C1-3 亚烷基或类似物，Y 是单键或类似物，Z 是 C1-3 亚烷基或类似物、R1和R2各自独立地为氢原子或类似物，R3、R4、R5和R6各自独立地为氢原子、卤素原子或类似物，具有抑制Aβ生成的作用或抑制BACE1的作用，可作为由Aβ引起的、以阿尔茨海默型痴呆为典型的神经退行性疾病的预防剂或治疗剂。